No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract: Neoadjuvant paclitaxel, trastuzumab, and pertuzumab regimen shows high cost-effectiveness for ERBB2-positive breast cancer

byTeddy Guo

December 23, 2020

in StudyGraphics

Reading Time: 1 min read

#Visual Abstract: Special Report: Vaccines in Development Part 1: Pfizer/BioNTech vaccine first to receive emergency use authorization

RelatedReports

Novel biodegradable sirolimus-eluting stents non-inferior to durable everolimus-eluting stents [BIOSCIENCE trial]

Cardiology

Paclitaxel-coated devices do not reduce rates of major amputations in chronic limb-threatening ischemia

October 31, 2025

Niraparib may lengthen progression-free survival for patients with recurrent ovarian cancer

Chronic Disease

Retifanlimab improves progression-free survival in advanced squamous cell anal carcinoma

July 24, 2025

Quick Take: Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma

Chronic Disease

Relacorilant plus nab-paclitaxel improves survival in platinum-resistant ovarian cancer patients

July 23, 2025

Exercise associated with decreased breast cancer risk

Oncology

Trastuzumab emtansine improves outcomes in residual HER2-positive breast cancer

March 7, 2025

Severe subtype of acute lymphoblastic leukemia susceptible to FDA-approved kinase inhibitors

Allogeneic anti-CD19 T cell therapy shows a manageable safety profile in pediatric and adult patients with high risk B-cell acute lymphoblastic leukemia

Mutation linked with decrease in cutaneous diffuse large B-cell lymphoma

Patients with hematological malignancies and concomitant COVID-19 have worse health outcomes

#VisualAbstract: Adjunctive methylprednisolone treatment for hepatitis B acute-on-chronic liver failure associated with increased survival

#VisualAbstract: Enteral water-soluble vitamin A in extremely preterm infants does not reduce severity of bronchopulmonary dysplasia

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports